Orphan Drug Pricing: More Dialogue And Collaboration Needed, Says EURORDIS
Executive Summary
Pharmaceutical companies, payers and other stakeholders need to work more collaboratively if the problems surrounding the pricing and reimbursement of orphan medicines are to be tackled successfully in Europe, says the rare disease organization EURORDIS.
You may also be interested in...
"Crazy" European Orphan Drug Pricing System Has To End
Eurordis head Yann Le Cam outlines his vision for the future of orphan drug pricing in Europe.
Witty On Pricing: Oncology 'No Safe Haven'
"It's time for industry and payers to start thinking about different pricing models, and it's going to require some transparency about what everything costs," said Sir Andrew Witty, speaking to Scrip on 18 April. "Lots of people will say pricing is not an issue in oncology. It's going to be an issue – it's inevitable."
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.